November 24, 2021Open Access

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study

AIAriel IsraelTel Aviv University EMEugene MerzonAriel University ASAlejandro A. SchäfferThe Wistar Institute

Key Points

Key points are not available for this paper at this time.

Abstract

In this large population of adults tested for SARS-CoV-2 by RT-PCR after two doses of mRNA BNT162b2 vaccine, a gradual increase in the risk of infection was seen for individuals who received their second vaccine dose after at least 90 days.

KI fragen

Bookmark

View Full Paper

Cite This Study

Israel et al. (Wed,) studied this question.

synapsesocial.com/papers/69d6b3be75cae9790bed88e0 https://doi.org/https://doi.org/10.1136/bmj-2021-067873

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection2021 · 223 citations
2Postlicensure Evaluation of COVID-19 Vaccines2020 · 64 citations
3SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-192021 · 25 citations
4Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?2021 · 507 citations
5Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine2020 · 15,594 citations

KI fragen

Bookmark

View Full Paper